Voya Investment Management LLC Trims Stock Position in Vera Therapeutics, Inc. $VERA

by · The Cerbat Gem

Voya Investment Management LLC lessened its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 2.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 416,376 shares of the company’s stock after selling 11,563 shares during the period. Voya Investment Management LLC owned approximately 0.65% of Vera Therapeutics worth $12,100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of VERA. Vestal Point Capital LP raised its position in shares of Vera Therapeutics by 132.6% in the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $60,050,000 after buying an additional 1,425,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Vera Therapeutics by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after acquiring an additional 377,783 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Vera Therapeutics by 89.3% during the second quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after purchasing an additional 336,978 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Vera Therapeutics during the second quarter worth about $7,044,000. Finally, JPMorgan Chase & Co. increased its position in shares of Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Stock Up 5.0%

Shares of NASDAQ VERA opened at $53.78 on Tuesday. The company has a market cap of $3.44 billion, a price-to-earnings ratio of -13.48 and a beta of 1.21. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. The firm’s fifty day moving average is $34.36 and its 200 day moving average is $27.41. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $54.57.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter in the previous year, the firm posted ($0.85) EPS. On average, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the transaction, the director owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares of the company’s stock, valued at $1,390,201.34. The trade was a 23.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 16.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on VERA shares. The Goldman Sachs Group increased their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen lifted their price target on Vera Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Pivotal Research set a $73.00 price objective on Vera Therapeutics in a research report on Friday, December 5th. Evercore ISI boosted their target price on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Wedbush lifted their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $74.83.

Get Our Latest Stock Analysis on VERA

Vera Therapeutics Company Profile

(Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

See Also

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report).